Breaking News Instant updates and real-time market news.

ICCC

Immucell

$8.92 /

-0.68 (-7.08%)

16:09
04/11/22
04/11
16:09
04/11/22
16:09

Immucell reports preliminary Q1 revenue $6M vs. $4.1M last year

"Sales during the first quarter ended March 31, 2022 increased by 46% to $6.0 million compared to the same period of the prior year, which is exciting for us," commented Michael Brigham, president and CEO of ImmuCell. "This favorable comparison does reflect tighter supply constraints during the first quarter of 2021 before the first level of investments to increase our production capacity had been completed."

OTHER BREAKING NEWS FROM THE FLY

General news
Market Update: » 03:40
12/06/22
12/06
03:40
12/06/22
03:40
$ECON

Economic Data

/

+

Market Update: European…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Conference/Events
Vigil Neuroscience to hold a KOL event » 23:35
12/05/22
12/05
23:35
12/05/22
23:35
VIGL

Vigil Neuroscience

$12.05 /

-0.07 (-0.58%)

Management provides…

Management provides details on the axonal spheroids and pigmented glia (ALSP) disease background and present the VGL101 Phase 2 Trial design and objectives at a KOL event to be held in New York on December 6 at 8:30 am. Webcast Link

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$12.05 /

-0.07 (-0.58%)

VIGL Vigil Neuroscience
$12.05 /

-0.07 (-0.58%)

09/15/22 Wedbush
Vigil Neuroscience initiated with an Outperform at Wedbush
09/15/22 Wedbush
Vigil Neuroscience initiated with an Outperform at Wedbush
08/29/22 H.C. Wainwright
Vigil Neuroscience initiated with a Buy at H.C. Wainwright
02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
VIGL Vigil Neuroscience
$12.05 /

-0.07 (-0.58%)

  • 07
    Jan
VIGL Vigil Neuroscience
$12.05 /

-0.07 (-0.58%)

Conference/Events
Vicarious Surgical to hold a virtual event » 23:25
12/05/22
12/05
23:25
12/05/22
23:25
RBOT

Vicarious Surgical

$2.81 /

-0.49 (-14.85%)

Management hosts a…

Management hosts a Virtual Demonstration Day to show the Company's Beta 2 surgical robot prototype for investors and analysts on December 6 at 11 am. Webcast Link

ShowHide Related Items >><<
RBOT Vicarious Surgical
$2.81 /

-0.49 (-14.85%)

RBOT Vicarious Surgical
$2.81 /

-0.49 (-14.85%)

07/18/22 BTIG
Vicarious Surgical price target lowered to $7 from $8 at BTIG
05/10/22 Piper Sandler
Vicarious Surgical price target lowered to $5 from $7 at Piper Sandler
03/04/22 Canaccord
Vicarious Surgical price target lowered to $13 from $15 at Canaccord
03/04/22 Piper Sandler
Vicarious Surgical downgraded to Neutral from Overweight at Piper Sandler
RBOT Vicarious Surgical
$2.81 /

-0.49 (-14.85%)

Conference/Events
Milestone Pharmaceuticals to hold a webcast » 23:15
12/05/22
12/05
23:15
12/05/22
23:15
MIST

Milestone Pharmaceuticals

$4.73 /

-0.22 (-4.44%)

Management holds a…

Management holds a webcast to discuss the commercial opportunity for Etripamil, the Company's lead investigational product, for treatment of patients with Paroxysmal Supra-Ventricular Tachycardia (PSVT) on December 6 at 1 pm. Webcast Link

ShowHide Related Items >><<
MIST Milestone Pharmaceuticals
$4.73 /

-0.22 (-4.44%)

MIST Milestone Pharmaceuticals
$4.73 /

-0.22 (-4.44%)

11/14/22 H.C. Wainwright
Milestone Pharmaceuticals price target raised to $25 from $20 at H.C. Wainwright
10/17/22 Piper Sandler
Piper sees 'blockbuster sales' for Milestone's etripamil
05/02/22 Piper Sandler
Milestone data support confidence in Phase III study, says Piper Sandler
04/21/22 Piper Sandler
Piper upgrades Milestone Pharmaceuticals on etripamil confidence
MIST Milestone Pharmaceuticals
$4.73 /

-0.22 (-4.44%)

MIST Milestone Pharmaceuticals
$4.73 /

-0.22 (-4.44%)

Hot Stocks
Cathie Wood's ARK Investment bought 162.7K shares of Verve Therapeutics today  20:17
12/05/22
12/05
20:17
12/05/22
20:17
VERV

Verve Therapeutics

$21.40 /

-2.57 (-10.72%)

 
ShowHide Related Items >><<
VERV Verve Therapeutics
$21.40 /

-2.57 (-10.72%)

VERV Verve Therapeutics
$21.40 /

-2.57 (-10.72%)

12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
08/24/22 Stifel
Verve Therapeutics upgraded to Buy at Stifel on upside from near-term catalysts
VERV Verve Therapeutics
$21.40 /

-2.57 (-10.72%)

  • 21
    Jul
VERV Verve Therapeutics
$21.40 /

-2.57 (-10.72%)

Hot Stocks
Coupang director sells $7.47M in common stock » 19:39
12/05/22
12/05
19:39
12/05/22
19:39
CPNG

Coupang

$17.92 /

-1.71 (-8.71%)

In a regulatory filing,…

In a regulatory filing, Coupang disclosed that its director Benjamin Sun sold 373K shares of common stock on December 1st in a total transaction size of $7.47M.

ShowHide Related Items >><<
CPNG Coupang
$17.92 /

-1.71 (-8.71%)

CPNG Coupang
$17.92 /

-1.71 (-8.71%)

12/01/22 New Street
Coupang initiated with a Buy at New Street
11/29/22 Bernstein
Coupang not gaining market share fast enough, says Bernstein
10/07/22 HSBC
Coupang initiated with a Buy at HSBC
08/16/22 CLSA
Coupang downgraded to Sell from Outperform at CLSA
CPNG Coupang
$17.92 /

-1.71 (-8.71%)

CPNG Coupang
$17.92 /

-1.71 (-8.71%)

CPNG Coupang
$17.92 /

-1.71 (-8.71%)

CPNG Coupang
$17.92 /

-1.71 (-8.71%)

Hot Stocks
NeoGenomics names Jeffrey Sherman as new CFO » 19:38
12/05/22
12/05
19:38
12/05/22
19:38
NEO

NeoGenomics

$11.81 /

+0.175 (+1.50%)

, PRVA

Privia Health

$23.52 /

-0.395 (-1.65%)

NeoGenomics (NEO)…

NeoGenomics (NEO) announced that Jeffrey S. Sherman will join the company as CFO effective December 7, 2022. Mr. Sherman succeeds William Bonello who will remain with the Company to provide transition and onboarding support for a period of time. Mr. Sherman served as the CFO of Privia Health Group (PRVA) a national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care.

ShowHide Related Items >><<
PRVA Privia Health
$23.52 /

-0.395 (-1.65%)

NEO NeoGenomics
$11.81 /

+0.175 (+1.50%)

NEO NeoGenomics
$11.81 /

+0.175 (+1.50%)

11/14/22 Piper Sandler
NeoGenomics price target lowered to $18 from $19 at Piper Sandler
08/26/22 Benchmark
NeoGenomics downgraded to Hold from Buy at Benchmark
08/22/22 Needham
Needham cuts NeoGenomics to Hold, sees 2023 as 'transition year'
08/22/22 Needham
NeoGenomics downgraded to Hold from Buy at Needham
PRVA Privia Health
$23.52 /

-0.395 (-1.65%)

11/15/22 Piper Sandler
Privia Health should be owned into Q4 report, says Piper Sandler
11/11/22 Canaccord
Privia Health price target lowered to $43 from $50 at Canaccord
09/07/22 Truist
Privia Health assumed with a Buy at Truist
09/01/22 Piper Sandler
Piper 'incrementally positive' on Privia, Signify after CMS data
PRVA Privia Health
$23.52 /

-0.395 (-1.65%)

NEO NeoGenomics
$11.81 /

+0.175 (+1.50%)

  • 17
    Nov
PRVA Privia Health
$23.52 /

-0.395 (-1.65%)

NEO NeoGenomics
$11.81 /

+0.175 (+1.50%)

Downgrade
Edwards Lifesciences downgraded to Hold from Buy at Stifel » 19:19
12/05/22
12/05
19:19
12/05/22
19:19
EW

Edwards Lifesciences

$73.86 /

-2.72 (-3.55%)

Stifel analyst Rick Wise…

Stifel analyst Rick Wise downgraded Edwards Lifesciences to Hold from Buy with a price target of $75, down from $95. The stock is down 43% year-to-date and already reflects some slower-than-expected U.S. TAVR growth and a slower TAVR market, the analyst tells investors in a research note. Wise adds however that his downgrade follows conversations with ten implanting physicians asserting that until a new TAVR indication is approved, growth will be limited due to patient population aging. The analyst further warns that TAVR growth rates may be-base lower for longer than consensus is estimating.

ShowHide Related Items >><<
EW Edwards Lifesciences
$73.86 /

-2.72 (-3.55%)

EW Edwards Lifesciences
$73.86 /

-2.72 (-3.55%)

12/01/22 Wolfe Research
Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
12/01/22 Wolfe Research
Edwards Lifesciences downgraded to Peer Perform from Outperform at Wolfe Research
11/28/22 RBC Capital
Edwards Lifesciences price target lowered to $105 from $118 at RBC Capital
11/16/22 Evercore ISI
Evercore ISI removes seven Healthcare Services and Tech stocks from 'TAP' list
EW Edwards Lifesciences
$73.86 /

-2.72 (-3.55%)

EW Edwards Lifesciences
$73.86 /

-2.72 (-3.55%)

EW Edwards Lifesciences
$73.86 /

-2.72 (-3.55%)

Hot Stocks
News Corp. special committee to explore combination with Fox Corp. » 19:13
12/05/22
12/05
19:13
12/05/22
19:13
FOXA

Fox Corp.

$32.02 /

-0.565 (-1.73%)

, NWS

News Corp.

$18.97 /

-0.465 (-2.39%)

)News Corp (NWS) Special…

)News Corp (NWS) Special Committee composed solely of independent and disinterested members of the News Corp Board of Directors "formed to explore a potential combination with Fox Corp (FOXA) following receipt of letters from K. Rupert Murdoch and the Murdoch Family Trust, provided an update on the process in response to recent investor inquiries. The Special Committee is made up of all the independent directors not affiliated with the Murdoch family--Kelly Ayotte, Jose Maria Aznar, Natalie Bancroft, Ana Paula Pessoa, Masroor Siddiqui-and is chaired by Mr. Siddiqui, News Corp's Lead Independent Director. The Special Committee has been delegated full authority to evaluate the Proposed Transaction. The letters indicated that Mr. Murdoch and the Murdoch Family Trust will not vote in favor of a transaction unless it is both recommended by the Special Committee and approved by a majority vote of the shares held by non-affiliated stockholders entitled to vote."

ShowHide Related Items >><<
NWS News Corp.
$18.97 /

-0.465 (-2.39%)

FOXA Fox Corp.
$32.02 /

-0.565 (-1.73%)

FOXA Fox Corp.
$32.02 /

-0.565 (-1.73%)

11/02/22 RBC Capital
Fox Corp. price target lowered to $38 from $46 at RBC Capital
11/02/22 Deutsche Bank
Fox Corp. price target lowered to $42 from $46 at Deutsche Bank
10/17/22 Morgan Stanley
Morgan Stanley says Fox-News combo would balance more scale with more complexity
10/17/22 Loop Capital
Fox Corp. downgraded to Hold from Buy at Loop Capital
NWS News Corp.
$18.97 /

-0.465 (-2.39%)

07/10/22 Goldman Sachs
News Corp. downgraded to Buy from Conviction Buy at Goldman Sachs
NWS News Corp.
$18.97 /

-0.465 (-2.39%)

FOXA Fox Corp.
$32.02 /

-0.565 (-1.73%)

NWS News Corp.
$18.97 /

-0.465 (-2.39%)

FOXA Fox Corp.
$32.02 /

-0.565 (-1.73%)

NWS News Corp.
$18.97 /

-0.465 (-2.39%)

FOXA Fox Corp.
$32.02 /

-0.565 (-1.73%)

Initiation
BrightSpire Capital initiated with a Buy at JonesTrading » 18:53
12/05/22
12/05
18:53
12/05/22
18:53
BRSP

BrightSpire Capital

$6.98 /

-0.005 (-0.07%)

JonesTrading analyst…

JonesTrading analyst Jason Stewart initiated coverage of BrightSpire Capital with a Buy rating and $11 price target. The company has a scaled balance sheet, diverse origination platform and demonstrated ability to manage assets across sectors, the analyst tells investors in a research note. Stewart contends that as volatility subsides and the demand for commercial real estate credit improves, BrightSpire is "in position to make opportunistic investments".

ShowHide Related Items >><<
BRSP BrightSpire Capital
$6.98 /

-0.005 (-0.07%)

03/11/22 BTIG
BrightSpire Capital coverage transferred at BTIG
02/18/22 BofA
BrightSpire Capital initiated with a Neutral at BofA
01/04/22 B. Riley
BrightSpire Capital shares can return 35%, says at B. Riley
12/17/21 JMP Securities
BrightSpire Capital initiated with an Outperform at JMP Securities
BRSP BrightSpire Capital
$6.98 /

-0.005 (-0.07%)

BRSP BrightSpire Capital
$6.98 /

-0.005 (-0.07%)

Hot Stocks
Territorial Bancorp announces $5M buyback » 18:46
12/05/22
12/05
18:46
12/05/22
18:46
TBNK

Territorial Bancorp

$22.60 /

-0.05 (-0.22%)

Territorial Bancorp…

Territorial Bancorp "announces that its Board of Directors has adopted its twelfth stock repurchase program. Under this repurchase program, the Company may repurchase up to $5,000,000 of the company's outstanding shares."

ShowHide Related Items >><<
TBNK Territorial Bancorp
$22.60 /

-0.05 (-0.22%)

05/02/22 Piper Sandler
Territorial Bancorp downgraded to Underweight from Neutral at Piper Sandler
TBNK Territorial Bancorp
$22.60 /

-0.05 (-0.22%)

Recommendations
Textron award estimated at $11 per share net present value, says Jefferies » 18:44
12/05/22
12/05
18:44
12/05/22
18:44
TXT

Textron

$69.93 /

-1.33 (-1.87%)

, LMT

Lockheed Martin

$490.74 /

-5.505 (-1.11%)

Jefferies analyst Sheila…

Jefferies analyst Sheila Kahyaoglu writes that the $80B future long-range assault aircraft program, awarded to Textron's (TXT) Bell V-280 by U.S. Army, could be a "$66B revenue generator through 2050", adding $11 to Textron stock's net present value. Kahyaoglu also contends that its V-280 tilt rotor is a "structurally better aircraft" as the decision to award the contract to Textron came despite the "very strong" showing from Lockheed Martin's (LMT) Sikorsky team.

ShowHide Related Items >><<
TXT Textron
$69.93 /

-1.33 (-1.87%)

LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

09/13/22 Bernstein
Textron initiated with a Market Perform at Bernstein
07/29/22 Susquehanna
Textron price target lowered to $84 from $90 at Susquehanna
07/28/22 BofA
Textron price target lowered to $70 from $74 at BofA
03/07/22 Jefferies
Textron's current levels 'could prove compelling,' says Jefferies
LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

12/05/22 Jefferies
Lockheed Martin price target raised to $525 from $500 at Jefferies
11/01/22 Canaccord
Terran Orbital price target lowered to $14 from $17 at Canaccord
10/19/22 RBC Capital
Lockheed Martin price target raised to $445 from $420 at RBC Capital
10/19/22 Susquehanna
Lockheed Martin price target lowered to $510 from $539 at Susquehanna
TXT Textron
$69.93 /

-1.33 (-1.87%)

LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

LMT Lockheed Martin
$490.74 /

-5.505 (-1.11%)

Hot Stocks
Owens Corning completes sale of Russian operations, affirms Q4 guidance » 18:42
12/05/22
12/05
18:42
12/05/22
18:42
OC

Owens Corning

$88.91 /

-2.23 (-2.45%)

Following its decision…

Following its decision earlier this year to exit the Russian market, Owens Corning announced that it has completed the sale of its operations in the country to Umatex, a Russia-based producer of carbon fiber and fiber-based items. Financial terms of the sale were not disclosed. In conjunction with the announcement, the company reaffirmed its guidance of modest growth in net sales and earnings for the enterprise in the fourth quarter compared with the same period in 2021.

ShowHide Related Items >><<
OC Owens Corning
$88.91 /

-2.23 (-2.45%)

OC Owens Corning
$88.91 /

-2.23 (-2.45%)

10/27/22 Credit Suisse
Owens Corning price target lowered to $90 from $98 at Credit Suisse
10/20/22 Deutsche Bank
Owens Corning price target lowered to $99 from $103 at Deutsche Bank
10/18/22 BofA
Owens Corning double upgraded to Buy at BofA
10/18/22 BofA
Owens Corning upgraded to Buy from Underperform at BofA
OC Owens Corning
$88.91 /

-2.23 (-2.45%)

OC Owens Corning
$88.91 /

-2.23 (-2.45%)

Hot Stocks
GM's BrightDrop adds DHL Express Canada to customer portfolio » 18:38
12/05/22
12/05
18:38
12/05/22
18:38
GM

General Motors

$38.79 /

-1.105 (-2.77%)

General Motors'…

General Motors' BrightDrop announced it had entered its first international market, Canada, adding DHL Express Canada to its customer portfolio. The company also announced production of the BrightDrop Zevo 600 electric delivery vans had begun at GM's CAMI Assembly plant in Ontario, making the facility Canada's first large-scale EV factory. BrightDrop offers a suite of products including the Zevo electric delivery vans, the Trace eCarts, and the BrightDrop Core software platform to reduce carbon emissions from last mile delivery while reducing urban congestion. The business launched in 2021 with a nearly $800M investment from its parent company GM to convert the CAMI Assembly plant to BrightDrop's high-volume EV production facility. Entering the Canadian market is BrightDrop's latest effort to address the $250B last-mile delivery industry, particularly as companies around the world set goals to electrify their fleets and optimize operations. DHL Express Canada plans to add its first BrightDrop Zevo electric delivery vans to its fleet early next year.

ShowHide Related Items >><<
GM General Motors
$38.79 /

-1.105 (-2.77%)

GM General Motors
$38.79 /

-1.105 (-2.77%)

11/18/22 Wedbush
GM's Investor Day event 'impressive,' says Wedbush
11/10/22 Wolfe Research
General Motors downgraded to Peer Perform from Outperform at Wolfe Research
10/26/22 Deutsche Bank
General Motors price target lowered to $35 from $36 at Deutsche Bank
10/26/22 JPMorgan
General Motors price target raised to $59 from $58 at JPMorgan
GM General Motors
$38.79 /

-1.105 (-2.77%)

GM General Motors
$38.79 /

-1.105 (-2.77%)

GM General Motors
$38.79 /

-1.105 (-2.77%)

GM General Motors
$38.79 /

-1.105 (-2.77%)

Downgrade
Steel Dynamics downgraded to Neutral from Buy at UBS » 18:37
12/05/22
12/05
18:37
12/05/22
18:37
STLD

Steel Dynamics

$106.75 /

-2.8 (-2.56%)

UBS analyst Andreas…

UBS analyst Andreas Bokkenheuser downgraded Steel Dynamics to Neutral from Buy.

ShowHide Related Items >><<
STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

11/14/22 BMO Capital
Steel Dynamics price target raised to $100 from $89 at BMO Capital
10/21/22 BMO Capital
Steel Dynamics price target raised to $89 from $77 at BMO Capital
10/06/22 Goldman Sachs
Steel Dynamics upgraded to Buy from Neutral at Goldman Sachs
07/06/22 Morgan Stanley
Steel Dynamics price target lowered to $78 from $94 at Morgan Stanley
STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

STLD Steel Dynamics
$106.75 /

-2.8 (-2.56%)

Hot Stocks
Wingstop CEO: Our business is experiencing meaningful deflation » 18:32
12/05/22
12/05
18:32
12/05/22
18:32
WING

Wingstop

$158.04 /

-4.96 (-3.04%)

In an interview on…

In an interview on CNBC's Mad money, Michael Skipworth said, "We've got plenty of inventory." He expects a favorable commodity backdrop for 2023 with strong comp growth. "We're set up for a 19th quarter of consecutive growth," he added.

ShowHide Related Items >><<
WING Wingstop
$158.04 /

-4.96 (-3.04%)

12/02/22 Deutsche Bank
Wingstop price target raised to $148 from $135 at Deutsche Bank
10/27/22 Truist
Wingstop price target raised to $132 from $125 at Truist
10/27/22 Stifel
Wingstop price target raised to $140 from $120 at Stifel
10/27/22 BTIG
Wingstop price target raised to $170 from $145 at BTIG
WING Wingstop
$158.04 /

-4.96 (-3.04%)

WING Wingstop
$158.04 /

-4.96 (-3.04%)

Hot Stocks
Navistar, ToSimple end co-development agreement » 18:32
12/05/22
12/05
18:32
12/05/22
18:32
TSP

TuSimple

$2.26 /

+0.05 (+2.27%)

, NAV

Navistar

$44.50 /

+ (+0.00%)

In a joint announcement,…

In a joint announcement, TuSimple (TSP) and Navistar (NAV) "announced an end to their co-development under the 2020 Joint Development Agreement. The decision to end the development agreement does not preclude the companies from working together in the future."

ShowHide Related Items >><<
TSP TuSimple
$2.26 /

+0.05 (+2.27%)

NAV Navistar
$44.50 /

+ (+0.00%)

TSP TuSimple
$2.26 /

+0.05 (+2.27%)

11/11/22 Truist
TuSimple downgraded to Hold at Truist after leadership shakeup
11/11/22 Truist
TuSimple downgraded to Hold from Buy at Truist
11/01/22 Oppenheimer
TuSimple downgraded to Perform from Outperform at Oppenheimer
11/01/22 JPMorgan
TuSimple downgraded to Underweight from Overweight at JPMorgan
NAV Navistar
$44.50 /

+ (+0.00%)

TSP TuSimple
$2.26 /

+0.05 (+2.27%)

TSP TuSimple
$2.26 /

+0.05 (+2.27%)

TSP TuSimple
$2.26 /

+0.05 (+2.27%)

TSP TuSimple
$2.26 /

+0.05 (+2.27%)

On The Fly
Fly Intel: After-Hours Movers » 18:29
12/05/22
12/05
18:29
12/05/22
18:29
GTLB

GitLab

$38.35 /

-2.92 (-7.08%)

, POWL

Powell

$26.88 /

+0.73 (+2.79%)

, EOLS

Evolus

$6.99 /

-0.315 (-4.31%)

, SUMO

Sumo Logic

$7.20 /

-0.585 (-7.51%)

, BIVI

BioVie

$5.18 /

-0.275 (-5.04%)

, MNOV

MediciNova

$2.49 /

-0.1 (-3.86%)

, TXT

Textron

$69.93 /

-1.33 (-1.87%)

, FNKO

Funko

$10.39 /

-0.12 (-1.14%)

, HLF

Herbalife Nutrition

$17.46 /

-0.225 (-1.27%)

, AXON

Axon

$184.22 /

-4.8 (-2.54%)

Check out this evening's…

ShowHide Related Items >><<
TXT Textron
$69.93 /

-1.33 (-1.87%)

SUMO Sumo Logic
$7.20 /

-0.585 (-7.51%)

MNOV MediciNova
$2.49 /

-0.1 (-3.86%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

FNKO Funko
$10.39 /

-0.12 (-1.14%)

EOLS Evolus
$6.99 /

-0.315 (-4.31%)

BIVI BioVie
$5.18 /

-0.275 (-5.04%)

AXON Axon
$184.22 /

-4.8 (-2.54%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

11/29/22 BofA
BofA ups GitLab target to $78 with survey suggesting Q3 beat
11/28/22 RBC Capital
GitLab price target lowered to $55 from $75 at RBC Capital
11/28/22 Piper Sandler
GitLab remains a top idea with $67 target at Piper Sandler
09/22/22 MoffettNathanson
GitLab initiated with a Buy at MoffettNathanson
POWL Powell
$26.88 /

+0.73 (+2.79%)

06/10/22 Sidoti
Powell downgraded to Neutral from Buy at Sidoti
03/29/22 Sidoti
Powell upgraded to Buy from Neutral at Sidoti
EOLS Evolus
$6.99 /

-0.315 (-4.31%)

06/23/22 Needham
Needham starts 'aesthetics emerging star' Evolus at Buy
06/23/22 Needham
Evolus initiated with a Buy at Needham
05/12/22 Barclays
Evolus upgraded to Equal Weight from Underweight at Barclays
04/28/22 Barclays
Evolus price target raised to $8 from $7 at Barclays
SUMO Sumo Logic
$7.20 /

-0.585 (-7.51%)

07/13/22 Piper Sandler
Sumo Logic price target lowered to $8 from $10 at Piper Sandler
05/27/22 Piper Sandler
Sumo Logic price target lowered to $10 from $12.50 at Piper Sandler
05/23/22 Jefferies
Sumo Logic price target lowered to $8.50 from $12 at Jefferies
05/23/22 RBC Capital
Sumo Logic price target lowered to $14 from $17 at RBC Capital
BIVI BioVie
$5.18 /

-0.275 (-5.04%)

07/22/22 Cantor Fitzgerald
BioVie initiated with an Overweight at Cantor Fitzgerald
03/14/22 Oppenheimer
BioVie initiated with an Outperform at Oppenheimer
01/24/22 B. Riley
BioVie price target lowered to $18 from $27 at B. Riley
MNOV MediciNova
$2.49 /

-0.1 (-3.86%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
TXT Textron
$69.93 /

-1.33 (-1.87%)

09/13/22 Bernstein
Textron initiated with a Market Perform at Bernstein
07/29/22 Susquehanna
Textron price target lowered to $84 from $90 at Susquehanna
07/28/22 BofA
Textron price target lowered to $70 from $74 at BofA
03/07/22 Jefferies
Textron's current levels 'could prove compelling,' says Jefferies
FNKO Funko
$10.39 /

-0.12 (-1.14%)

11/07/22 BMO Capital
Funko price target lowered to $10 from $22 at BMO Capital
11/07/22 BofA
Funko downgraded to Neutral at BofA on challenging outlook for holidays
11/07/22 BofA
Funko downgraded to Neutral from Buy at BofA
11/04/22 DA Davidson
Funko price target lowered to $20 from $48 at DA Davidson
HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

11/01/22 B. Riley
Herbalife Nutrition price target lowered to $31 from $38 at B. Riley
11/01/22 Citi
Herbalife Nutrition price target lowered to $26 from $30 at Citi
10/05/22 Citi
Herbalife Nutrition price target lowered to $30 from $36 at Citi
08/03/22 B. Riley
Herbalife Nutrition price target lowered to $38 from $41 at B. Riley
AXON Axon
$184.22 /

-4.8 (-2.54%)

11/09/22 Northland
Axon price target raised to $160 from $140 at Northland
11/09/22 Credit Suisse
Axon price target raised to $152 from $142 at Credit Suisse
09/15/22 Barclays
Axon initiated with an Overweight at Barclays
08/18/22 Baird
Axon price target raised to $150 from $130 at Baird
TXT Textron
$69.93 /

-1.33 (-1.87%)

SUMO Sumo Logic
$7.20 /

-0.585 (-7.51%)

POWL Powell
$26.88 /

+0.73 (+2.79%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

FNKO Funko
$10.39 /

-0.12 (-1.14%)

EOLS Evolus
$6.99 /

-0.315 (-4.31%)

AXON Axon
$184.22 /

-4.8 (-2.54%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

FNKO Funko
$10.39 /

-0.12 (-1.14%)

BIVI BioVie
$5.18 /

-0.275 (-5.04%)

AXON Axon
$184.22 /

-4.8 (-2.54%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

HLF Herbalife Nutrition
$17.46 /

-0.225 (-1.27%)

GTLB GitLab
$38.35 /

-2.92 (-7.08%)

Hot Stocks
Ulta Beauty CEO: Consumer is loving what we are offering » 18:25
12/05/22
12/05
18:25
12/05/22
18:25
ULTA

Ulta Beauty

$472.42 /

+0.865 (+0.18%)

In an interview on…

In an interview on CNBC's Mad Money, Dave Kimbell said Ulta saw broad based strength across the business in Q3. The company's positive culture is holding it together and attracting new talent, Kimball said. "We are staffed and ready to go for the holiday season." Ulta continues to bring in new customers and reactivate old ones, with Gen Z representing a strong growth opportunity, Kimbell noted.

ShowHide Related Items >><<
ULTA Ulta Beauty
$472.42 /

+0.865 (+0.18%)

ULTA Ulta Beauty
$472.42 /

+0.865 (+0.18%)

12/05/22 Barclays
Ulta Beauty price target raised to $548 from $511 at Barclays
12/02/22 DA Davidson
Ulta Beauty price target raised to $545 from $490 at DA Davidson
12/02/22 Deutsche Bank
Ulta Beauty price target raised to $607 from $589 at Deutsche Bank
12/02/22 Baird
Ulta Beauty price target raised to $550 from $500 at Baird
ULTA Ulta Beauty
$472.42 /

+0.865 (+0.18%)

ULTA Ulta Beauty
$472.42 /

+0.865 (+0.18%)

ULTA Ulta Beauty
$472.42 /

+0.865 (+0.18%)

Hot Stocks
LGI Homes announces 412 home closings in November » 18:17
12/05/22
12/05
18:17
12/05/22
18:17
LGIH

LGI Homes

$98.15 /

-1.29 (-1.30%)

LGI Homes "announced…

LGI Homes "announced it closed 412 homes in November 2022. As of November 30, 2022, the company had 92 active selling communities."

ShowHide Related Items >><<
LGIH LGI Homes
$98.15 /

-1.29 (-1.30%)

LGIH LGI Homes
$98.15 /

-1.29 (-1.30%)

11/22/22 JPMorgan
LGI Homes price target raised to $84 from $73 at JPMorgan
10/10/22 Wedbush
LGI Homes price target lowered to $84 from $94 at Wedbush
08/03/22 JMP Securities
LGI Homes price target lowered to $140 from $175 at JMP Securities
07/12/22 JPMorgan
LGI Homes price target lowered to $77 from $85 at JPMorgan
LGIH LGI Homes
$98.15 /

-1.29 (-1.30%)

Hot Stocks
Palo Alto Networks director sells $6.4M in common stock » 18:15
12/05/22
12/05
18:15
12/05/22
18:15
PANW

Palo Alto Networks

$170.05 /

-2.69 (-1.56%)

In a regulatory filing,…

In a regulatory filing, Palo Alto Networks disclosed that its CTO Nir Zuk sold 36K share of common stock on December 1st in a total transaction size of $6.4M.

ShowHide Related Items >><<
PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

12/01/22 Redburn
Palo Alto Networks initiated with a Buy at Redburn
11/18/22 Evercore ISI
Palo Alto Networks price target raised to $215 from $207 at Evercore ISI
11/18/22 BMO Capital
Palo Alto Networks price target raised to $225 from $218 at BMO Capital
11/18/22 Morgan Stanley
Palo Alto Networks 'ready to re-rate,' says Morgan Stanley
PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

PANW Palo Alto Networks
$170.05 /

-2.69 (-1.56%)

Hot Stocks
Textron's Bell V-280 Valor chosen as U.S. Army long-range assault aircraft » 18:14
12/05/22
12/05
18:14
12/05/22
18:14
TXT

Textron

$69.93 /

-1.33 (-1.87%)

Textron "announced…

Textron "announced that Bell Textron Inc., a Textron company, has been awarded the development contract for the U.S. Army's Future Long-Range Assault Aircraft program. The award is based on Bell's V-280 Valor tiltrotor that was developed and tested as part of the Joint Multi-Role Technology Demonstrator program that began in 2013. The V-280 progressed through design, manufacturing, and more than three years of rigorous flight testing that provided extensive data validating the technical and operational advantages of the aircraft for the long-range assault mission. The initial contract refines the weapon system design, sustainment, digital enterprise, manufacturing, systems integration, flight-testing, and airworthiness qualification."

ShowHide Related Items >><<
TXT Textron
$69.93 /

-1.33 (-1.87%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

09/13/22 Bernstein
Textron initiated with a Market Perform at Bernstein
07/29/22 Susquehanna
Textron price target lowered to $84 from $90 at Susquehanna
07/28/22 BofA
Textron price target lowered to $70 from $74 at BofA
03/07/22 Jefferies
Textron's current levels 'could prove compelling,' says Jefferies
TXT Textron
$69.93 /

-1.33 (-1.87%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

TXT Textron
$69.93 /

-1.33 (-1.87%)

Hot Stocks
Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials » 18:08
12/05/22
12/05
18:08
12/05/22
18:08
MRTX

Mirati Therapeutics

$92.78 /

-3.05 (-3.18%)

Mirati Therapeutics…

Mirati Therapeutics announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the tolerability and feasibility of a concurrent combination regimen of a KRASG12C inhibitor and a PD-1/L1 checkpoint inhibitor. The KRYSTAL-7 and KRYSTAL-1 trials represent the largest dataset evaluating a KRASG12C inhibitor in combination with a PD-1/L1 checkpoint inhibitor as a first-line treatment for patients with NSCLC harboring a KRASG12C mutation. 75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months. Treatment-related adverse events were Grade 1-2 (39%), Grade 3 (40%) and Grade 4 (4%); there were no Grade 5 TRAEs observed. TRAEs led to discontinuation of both adagrasib and pembrolizumab in 2 patients and only pembrolizumab in 2 patients; there were no patients who discontinued only adagrasib due to a TRAE. Increases in alanine transaminase/ aspartate transaminase were consistent with either agent as a monotherapy with Grade 3 TRAEs being highest grade and total incidence of Grade 3 liver function test increases of 9%. Median time from onset to an increase in ALT and AST was 26 and 37 days, respectively and only 1 patient experienced new onset treatment-related ALT/AST increase after 3 months. Of patients who were clinically evaluable and received at least one on-study scan, adagrasib and pembrolizumab demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate of 49%. In a subset of response-evaluable patients enrolled at least 6 months prior to the data cutoff date, 6 of 26 clinical responses occurred at second on-study scan or later, and the ORR was 56%. 7 evaluable patients enrolled in the KRYSTAL-1 Phase 1b cohort reported an ORR of 57% and a disease control rate of 100%. The four patients who responded maintained response for over nine months while two continued to receive treatment and remain in response beyond 18 months. Safety in the KRYSTAL-1 Phase 1b cohort was consistent with what has been observed in KRSTYAL-7 and demonstrated a manageable safety profile with no Grade 4-5 TRAEs. "Initial results across all cohorts suggest the concurrent combination of adagrasib and pembrolizumab may provide a chemotherapy-free option for treatment-naive NSCLC with a manageable safety profile and encouraging clinical activity," said Pasi A. Janne, MD, PhD, Dana Farber Cancer Institute. "Across all evaluated cohorts, liver-related TRAEs were predominantly low grade and occurred early in treatment, with limited new onset after 3 months."

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

12/02/22 Piper Sandler
Mirati trial continuation 'tilts the scale for a positive outcome,' says Piper
11/22/22 BMO Capital
BMO says Mirati could be valued at up to $200 per share in 'upside scenario'
11/16/22 Citi
Mirati Therapeutics price target lowered to $121 from $127 at Citi
10/28/22 B. Riley
Mirati Therapeutics initiated with a Neutral at B. Riley
MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

MRTX Mirati Therapeutics
$92.78 /

-3.05 (-3.18%)

Hot Stocks
MediciNova says MN-166 trial analysis results published in journal » 18:01
12/05/22
12/05
18:01
12/05/22
18:01
MNOV

MediciNova

$2.49 /

-0.1 (-3.86%)

MediciNova, Inc., a…

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 in alcohol use disorder were published in The American Journal of Drug and Alcohol Abuse. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray, Professor, Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, Brain Research Institute at the University of California at Los Angeles and was funded by the National Institute on Drug Abuse. Topline results from a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in 52 non-treatment seeking individuals with AUD found that MN-166 reduced heavy drinking and attenuated neural cue-reactivity compared to placebo. Neural and peripheral inflammation has been implicated in the development and maintenance of AUD, as evidenced by increased inflammation in such individuals. A secondary analysis of this study was performed to determine if participants with elevated peripheral levels of proinflammatory proteins, specifically C-reactive protein, would show a greater benefit from MN-166 as assessed by clinical and biological outcomes.

ShowHide Related Items >><<
MNOV MediciNova
$2.49 /

-0.1 (-3.86%)

MNOV MediciNova
$2.49 /

-0.1 (-3.86%)

01/24/22 B. Riley
MediciNova price target lowered to $6 from $11 at B. Riley
Hot Stocks
Gol Linhas announces preliminary November traffic figures » 18:01
12/05/22
12/05
18:01
12/05/22
18:01
GOL

Gol Linhas

$2.91 /

-0.24 (-7.63%)

Highlights: GOL's…

Highlights: GOL's total supply increased 29.7%. Total seats increased 29.2% and the number of departures increased by 26.5%. GOL's total demand increased by 28.5% and the load factor was 81.3%. GOL's domestic supply increased 19.6% and demand increased by 18.7%. GOL's domestic load factor was 81.8%. The volume of departures increased by 22.1% and seats increased by 24.8%. GOL's international supply was 350M, the demand was 269M and international load factor was 76.9%.

ShowHide Related Items >><<
GOL Gol Linhas
$2.91 /

-0.24 (-7.63%)

GOL Gol Linhas
$2.91 /

-0.24 (-7.63%)

07/19/22 Deutsche Bank
Gol Linhas price target lowered to $6 from $10 at Deutsche Bank
07/06/22 Barclays
Gol Linhas downgraded to Equal Weight from Overweight at Barclays
04/26/22 Seaport Global
Gol Linhas upgraded to Buy from Neutral at Seaport Global
03/07/22 Seaport Global
Gol Linhas downgraded to Neutral from Buy at Seaport Global
GOL Gol Linhas
$2.91 /

-0.24 (-7.63%)

GOL Gol Linhas
$2.91 /

-0.24 (-7.63%)

GOL Gol Linhas
$2.91 /

-0.24 (-7.63%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.